09969.HK
InnoCare Pharma Limited
HKSE · Healthcare · Biotechnology · CN
HKD 15.37
+4.06%Aug 24, 2026, 09:32 UTC
InnoCare Pharma announced its first-half 2026 results, reporting a net profit of 246 million yuan, turning from a loss in the same period last year.
Aug 4, 2026, 01:00 UTC
InnoCare announced that its combination of orelabrutinib and mesutoclax was granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of patients with marginal zone lymphoma who have received at least one prior therapy.
Source:Jul 27, 2026, 09:42 UTC
InnoCare Pharma announced that its TYK2 inhibitor fadeucravacitinib (ICP-488) achieved the primary endpoint in a Phase III registrational trial for moderate-to-severe plaque psoriasis.
Source:Jul 20, 2026, 09:38 UTC
Directors Jisong Cui, Renbin Zhao, and Xiangyang Chen of InnoCare Pharma reduced their holdings of the company's A shares through centralized bidding.
Source:Jul 16, 2026, 08:43 UTC
Incyte announced positive Phase 2 results for its drug soficitinib in treating non-segmental vitiligo, meeting the primary endpoint.
Jul 15, 2026, 10:44 UTC
Inncare Bio announced that its phase 3 clinical trial for soficitinib (ICP-332) in treating moderate-to-severe atopic dermatitis met its primary endpoint.
Source:Jul 6, 2026, 01:00 UTC
InnoCare Pharma dosed the first patient in a clinical trial of its novel CDH17 targeted ADC ICP-B208 in China.
Source: